Zoledronic acid is used to treat certain bone diseases, including osteoporosis and Paget's disease of bone, and to manage bone metastases in patients with certain types of cancer [1][2]. It is also used to treat hypercalcemia of malignancy, a condition where cancer causes high calcium levels in the blood [3].
What is Zoledronic Acid Used For in Cancer Patients?
In cancer patients, zoledronic acid is primarily used to prevent skeletal-related events, such as fractures, spinal cord compression, and the need for radiation or surgery to bone [1]. It is also employed to lower high calcium levels in the blood caused by certain cancers [3]. Zoledronic acid has been studied and used in patients with breast cancer, multiple myeloma, and prostate cancer, among others, to address bone-related complications [1].
How Does Zoledronic Acid Work?
Zoledronic acid is a bisphosphonate that works by slowing down bone breakdown [4]. It inhibits osteoclast activity, which are cells responsible for resorbing bone tissue [4]. By reducing bone resorption, zoledronic acid helps to strengthen bones and reduce the risk of fractures and other bone complications [4].
What is the Difference Between Zoledronic Acid and Other Bisphosphonates?
Zoledronic acid is a potent, nitrogen-containing bisphosphonate [1]. Compared to older bisphosphonates like alendronate or risedronate, zoledronic acid is typically administered intravenously and is considered to have a higher potency [5]. This potency allows for less frequent dosing, often once per year for osteoporosis [5]. Other bisphosphonates can be taken orally or intravenously, with varying dosing schedules [5].
When Does Zoledronic Acid Patent Expiry Occur?
Information regarding the specific patent expiry dates for zoledronic acid and its formulations is available through specialized databases. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can provide details on when exclusivity periods are set to end [6].
What are the Side Effects of Zoledronic Acid?
Common side effects of zoledronic acid include flu-like symptoms, fever, muscle pain, and fatigue, particularly after the first infusion [7]. Other potential side effects can involve kidney problems, and a rare but serious risk is osteonecrosis of the jaw (ONJ), where bone in the jaw does not heal after injury or extraction [7][8]. Atypical femur fractures are another recognized risk associated with long-term bisphosphonate use, including zoledronic acid [8].
How is Zoledronic Acid Administered?
Zoledronic acid is administered intravenously, meaning it is given through a needle into a vein [2]. For osteoporosis, infusions are typically given once a year [5]. For cancer-related bone issues or hypercalcemia, it may be administered every 3-4 weeks, depending on the specific condition and the patient's response [1][3].
Who Manufactures Zoledronic Acid?
Zoledronic acid is available under brand names such as Zometa and Reclast, manufactured by Novartis. Generic versions are also available from various pharmaceutical companies [9].
What are the Clinical Trial Results for Zoledronic Acid?
Clinical trials have demonstrated the efficacy of zoledronic acid in reducing the incidence of skeletal-related events in patients with bone metastases from breast cancer, multiple myeloma, and prostate cancer [1]. Studies also show its effectiveness in increasing bone mineral density and reducing fracture risk in postmenopausal women with osteoporosis [1]. For hypercalcemia of malignancy, trials have shown zoledronic acid to be effective in lowering serum calcium levels [3].
Can Zoledronic Acid be Used in Children?
The use of zoledronic acid in children is generally limited and often considered off-label, with careful consideration of risks and benefits [10]. Its use in pediatric oncology is primarily focused on preventing skeletal-related events in specific circumstances where standard treatments are insufficient [10].
Sources:
[1] https://www.drugpatentwatch.com/drug/zoledronic-acid
[2] https://www.nhs.uk/medicines/zoledronic-acid/
[3] https://www.cancer.gov/publications/drug-summary/zoledronic-acid
[4] https://www.ncbi.nlm.nih.gov/books/NBK547669/
[5] https://www.rheumatology.org/Portals/0/Files/Bisphosphonates.pdf
[6] https://www.drugpatentwatch.com/
[7] https://www.mayoclinic.org/drugs-supplements/zoledronic-acid-intravenous-route/side-effects/drh-20069523
[8] https://www.bones.org/about-oa/patients/types-of-bone-disease/osteoporosis/bisphosphonate-therapy-and-bone-health/
[9] https://www.goodrx.com/zoledronic-acid
[10] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682765/